Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 7 selected

Guidance programme

Showing 1 to 10 of 1754

TitleReference numberPublishedLast updated
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and overTA1031
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)TA1028
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)TA1029
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1030
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Overweight and obesity managementNG246
Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adultsIPG799
Tebentafusp for treating advanced uveal melanomaTA1027
Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasiaIPG798
Tirzepatide for managing overweight and obesityTA1026

Results per page

  1. 10
  2. 25
  3. 50
  4. All